title: Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.
abstract: Insulinlike growth factor 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF- binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment with high-dose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 microg/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 microg/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of prognosis. After 80 months of follow-up, myeloma patients with low levels (< 13 nM) of serum IGF-1 had not reached median survival. In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression.
authors.affiliation: Institute of Cancer Research and Molecular Biology, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. therese.standal@medisin.ntnu.no
authors.forename: Therese
authors.initials: T
authors.lastname: Standal
authors.forename: Magne
authors.initials: M
authors.lastname: Borset
authors.forename: Stig
authors.initials: S
authors.lastname: Lenhoff
authors.forename: Finn
authors.initials: F
authors.lastname: Wisloff
authors.forename: Berit
authors.initials: B
authors.lastname: Stordal
authors.forename: Anders
authors.initials: A
authors.lastname: Sundan
authors.forename: Anders
authors.initials: A
authors.lastname: Waage
authors.forename: Carina
authors.initials: C
authors.lastname: Seidel
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I